## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `wolverine-stack`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/wolverine-stack/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/wolverine-stack/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/wolverine-stack/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/wolverine-stack/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/wolverine-stack/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/wolverine-stack/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `wolverine-stack` v14 · content_hash `3a16f4553a0a7c62…` · thread_head obj-270
- **thesis (c1):** BPC-157 is thought to work on the blood supply step of repair, growing new vessels into damaged tissue by switching on VEGF and the nitric oxide system that widens vessels.
  - c2 [mechanistic/active] TB-500 is a seven-amino-acid fragment of thymosin beta-4, covering residues 17 to 23 with the front end capped, and the stretch it copies is the part that grabs
  - c400 [mechanistic/active] Grabbing actin frees up the internal scaffolding a repair cell uses to crawl into a wound.
  - c3 [mechanistic/active] Tendon, ligament and the adult disc between two vertebrae all heal slowly because blood barely reaches them.
  - c401 [mechanistic/active] The centre of an adult disc has no vessels in it at all. It is fed by seepage across cartilage end plates that stiffen and calcify as a person gets older.
  - c4 [preclinical/active] In a rat Achilles tendon repair, TB-500 at 60 micrograms per kilogram per day raised the maximum load the tendon took before failing, against control, at p < 0.
  - c402 [preclinical/active] That experiment ran 32 rats, 8 to a group, with a daily injection into the belly for four weeks.
  - c5 [preclinical/active] In that same experiment TB-500 improved the Bonar tissue score at p = 0.016 and the Movin score at p = 0.017.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 1 open · strongest: Evidence handling strong. Residual chrome and density. Combination claims correctly limited. → https://miscsubjects.com/api/articles/wolverine-stack/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/wolverine-stack/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `wolverine-stack`
- **title:** The Wolverine stack: BPC-157 and TB-500, the evidence, the dosing arithmetic and the eight-week cost
- **url:** https://miscsubjects.com/a/wolverine-stack
- **register:** essay
- **updated:** 2026-08-04T22:08:38.210Z
- **tags:** peptide, bpc-157, tb-500, stack, tendon, wolverine

## Body

The Wolverine stack is two compounds taken at the same time: BPC-157 and TB-500. People run it after a tendon tear, a bad shoulder, a knee that will not settle, a disc that has been hurting for months. The reason they are run together is not that one is stronger. It is that each one is proposed to fix a different step of the same repair job, so the argument goes that they should not overlap.

The evidence state, up front. No controlled study has ever given both compounds to a person, in any condition, so the number of people who have taken the pair under measurement is nought. Separately the two are not equal. BPC-157 has five published human studies covering about 130 people, and not one of them is a finished controlled trial in a torn or worn tissue. The seven-amino-acid fragment sold as TB-500 has no human study at all and no established human dose. Two entries appeared on ClinicalTrials.gov in February 2026, filed by the same sponsor, Hudson Biotech: NCT07437547, a 120-person randomised, double-blind, placebo-controlled hamstring trial marked recruiting, and NCT07487363, which names TB-500 and whose own public summary states that it is a fictional example of a registry record. Neither has reported anything, and a registry filing is not a result. The animal record behind the pairing is rats, mice and rabbits — roughly 150 animal papers for BPC-157, a much smaller tendon and wound literature for the fragment — and the one experiment that ever put both compounds into the same rats found the combination beat neither compound on its own. What has never been measured in a person: the pair, at any dose, in any tissue, for any length of time.

One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason.

This page sets out what each step is, how good the evidence is for each, what happened the one time somebody put both compounds into the same animals, what a run costs to the dollar, and what forty people who tried it wrote down afterwards.

## Two compounds aimed at two different steps of the same repair

Damaged tendon, ligament and disc all repair in the same order. Blood has to reach the damaged spot. Repair cells have to crawl in from the surrounding tissue. Those cells have to lay down new collagen in ordered fibres rather than a random scar. Each step gates the next.

BPC-157 is proposed to act on the first step. In animals it grows new blood vessels into damaged tissue, mostly by switching on a growth signal called VEGF and the nitric-oxide system that widens vessels.

TB-500 is proposed to act on the second. It is a seven-amino-acid piece of a natural protein, thymosin beta-4, and the piece it copies is the part that grabs actin — the protein filament a cell builds and dismantles to change shape and crawl. Bind actin, and the cell's crawling machinery is freed up. A cell that cannot rebuild its own internal skeleton cannot move into a wound at all.

That is the whole logic of the pairing. One opens the supply line, the other moves the workforce down it. Nothing in the pairing addresses a torn fibre mechanically, and nothing in it dissolves a bulged disc.

[[embed:bpc-157]]

[[embed:tb-500]]

## The bottleneck in tendon, ligament and disc is blood, and both compounds are aimed at it

A muscle bruise heals in weeks. A tendon takes months. A spinal disc, in an adult, barely heals at all. The difference is blood supply. Muscle is dense with vessels. Tendon has few. The centre of an adult disc has none — nutrients cross in by seeping through the cartilage end plates, which themselves stiffen and calcify with age.

That single fact is why both compounds are attractive on paper for these tissues and why neither has been shown to work in them. A drug aimed at growing vessels into a structure that has almost no vessels is aimed at the real rate-limiting step. It is also aimed at the hardest possible target, and the harder the target, the more the argument needs measurements rather than mechanism.

## What each one is proposed to build back, and what would prove it wrong

| Compound | What it is proposed to do, in plain words | Strongest evidence behind that | What it adds that the other does not | What would prove it wrong |
|---|---|---|---|---|
| BPC-157 | Grow new blood vessels into damaged tissue and keep the repair cells there alive, so the site gets oxygen and raw material | Rat Achilles tendon torn off the bone and reattached came back mechanically stronger; cut ligament, crushed muscle and severed muscle-tendon join all healed faster than controls | The supply line. TB-500 does not act on the vessel-growth signal | A controlled animal study measuring blood vessel counts at the injury site showing no difference against control, or a human trial in tendon pain showing no separation from placebo |
| TB-500 | Free up the internal scaffolding cells use to crawl, so repair cells reach the wound and lay ordered fibres rather than scar | Rat Achilles repair, 8 animals per arm, four weeks: higher load to failure than control (p < 0.05), better tissue score (p = 0.016), most ordered collagen of any arm under stain | The workforce. BPC-157 does not bind actin | A study measuring cell arrival at the wound showing no increase, or the same tendon model repeated at a larger size with no strength difference |
| The pair together | Both steps at once, on the theory that a supply line without workers and workers without a supply line each stall | One study, in rats, found the combination did not beat either compound alone | Nothing that has been measured | Already partly answered — see the section below |

The evidence grade is the same for both compounds and it is worth naming plainly: controlled animal experiments in the target tissue, no controlled human experiment in any tissue that hurts.

## The strongest single-compound results, best first

| Rank | Finding | Species and model | Numbers | What it establishes |
|---|---|---|---|---|
| 1 | TB-500 raised maximum load to failure in a repaired Achilles tendon | Rat, tendon cut across and stitched, four weeks | 32 rats, 8 per arm, 60 µg/kg/day into the belly cavity, p < 0.05 | The only controlled measurement of mechanical strength for either compound in a repaired tendon |
| 2 | BPC-157 healed a tendon torn off the bone | Rat, Achilles detached from the heel bone | Faster reattachment and greater strength than control | The structural claim in the tissue people buy it for |
| 3 | BPC-157 sped recovery of a cut sciatic nerve | Rat, nerve cut and repaired | Faster return of function than control | The closest thing to a nerve result either compound has |
| 4 | BPC-157 improved recovery after spinal cord injury | Rat, PMID 31266512 | Better function than control, sustained | Shows the compound reaches and acts on nervous tissue given by mouth or by injection away from the site |
| 5 | Full-length thymosin beta-4 healed a cut knee ligament | Rat, ligament cut, 1 µg placed in the gap in fibrin glue | Uniform fibre bundles, significantly greater mechanical strength | The ligament result — but with the full 43-amino-acid protein, placed in the wound, not the 7-amino-acid fragment injected into fat |
| 6 | Thymosin beta-4 closed skin wounds faster | Rat, full-thickness wound | Surface regrown 42% faster at four days, 61% at seven; more collagen, more vessels | The original result the whole thymosin beta-4 literature rests on |

Rows 5 and 6 carry a caveat that changes how they read. They used full-length thymosin beta-4, a 43-amino-acid protein. What is sold as TB-500 is a 7-amino-acid piece of it, residues 17 to 23, with the front end capped. The two are not the same molecule, and FDA wrote that distinction down in July 2026. Reading a full-length result onto a fragment vial is the single most common error in this area.

Three separate orthopaedic and sports medicine reviews published in 2026 — in Sports Medicine, in the American Journal of Sports Medicine, and in the Journal of the American Academy of Orthopaedic Surgeons — went through this same literature independently and reached the same place: the animal record is real, the human record is not there, and the products on sale are unregulated.

[[embed:source:s34]]

[[embed:source:s35]]

## Somebody finally put both in the same rats, and the pair beat neither one alone

In July 2026 a Turkish orthopaedic group published the only experiment that has ever tested BPC-157 and TB-500 together against each one alone. Biçer and colleagues, in Joint Diseases and Related Surgery, PMID 42542926.

The design, in full: 32 rats, Achilles tendon cut across and surgically repaired, then four weeks of daily injection into the belly cavity, split into four groups of eight — nothing, BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, or both together. Outcomes were maximum load to failure on a testing machine, plus two scored measures of tissue quality read under a microscope by people blinded to the group.

The results:

- TB-500 alone raised maximum load to failure against control, p < 0.05.
- TB-500 alone improved the Bonar tissue score, p = 0.016, and the Movin score, p = 0.017.
- Under a collagen stain, the TB-500 group had the most ordered type I collagen fibres.
- BPC-157 alone came out numerically better than control and did not reach significance on total scores.
- The combination, in the authors' own words, "did not confer additional benefits compared to either agent alone."

That is the sentence the stack has to survive. Two compounds sold as a pair, tested as a pair for the first time, and the pair was no better than the better of the two.

The authors' reading is that the two probably converge on shared downstream machinery — that once the repair programme is running, pushing it from two directions does not push it further.

[[embed:source:s1]]

## Four reasons that one experiment does not close the question

Each of these is a real experiment somebody could run, not a hedge.

**One tissue.** The test was a surgically repaired Achilles tendon in a rat. Tendon has some blood supply. The place the stack is most often aimed at — a spinal disc — has almost none, and the argument for BPC-157 is specifically about growing vessels where there are none. The measurement that would answer this: run the same four-arm design in a disc model, or in a tissue with a poorer blood supply than tendon.

**One dose level each.** BPC-157 got 10 µg/kg/day, TB-500 got 60 µg/kg/day, and nothing else was tried. If either compound's effect rises and then falls as the dose goes up — which is normal for signalling peptides and which the ARA-290 human trials actually showed, where 4 mg worked and 8 mg did not — then a single dose pair tests one point on a surface, not the surface. The measurement: a dose grid, three levels of each compound, nine combination arms.

**A possible ceiling.** TB-500 alone already reached significance on strength and on both tissue scores. If a stitched rat tendon at four weeks heals about as well as that model allows, then a combination has no room left to show a difference, and a null result means the ruler ran out, not that the second compound is inert. The measurement: repeat with a harder injury — a larger gap, a delayed repair, or an older animal — so the control arm heals badly and there is space above it.

**Four weeks.** Dosing and measurement both stopped at four weeks. Collagen in a healing tendon keeps remodelling for months, and the ordered-fibre finding is exactly the sort of thing that could diverge later. The measurement: the same design read at twelve and twenty-four weeks.

None of those four is an argument that the combination works. They are the reasons the single null result does not settle it, and each one names the study that would.

## The experiment that would settle it

A single trial would answer more than everything above. Take a tendon or ligament injury model with a poor blood supply and a control arm that heals badly. Run four arms at three dose levels each — nothing, BPC-157, TB-500, both — with 15 to 20 animals per arm rather than 8, dosed under the skin rather than into the belly cavity, because under the skin is how humans take it. Measure load to failure, blood vessel counts at the wound, and ordered collagen, at four weeks and at sixteen. Pre-register the dose grid.

That study costs a fraction of one human trial and nobody has run it.

Nothing has ever tested three of these compounds together, in any species, at any dose. Adding ARA-290 to this pair for nerve pain is set out separately, and the three-compound combination has zero experimental record of any kind.

[[embed:wolverine-stack-ara-290]]

## No person has ever been given this pair in a controlled study

Here is that fact as one row, with what does exist beside it.

| Question | Answer | Basis |
|---|---|---|
| Controlled human trial of BPC-157 and TB-500 together | None, in any condition | Registry and literature searches return nothing |
| Controlled human trial of TB-500 alone by injection | None, by any route | FDA's July 2026 review states it has found no human exposure data for products containing the fragment |
| Controlled human trial of BPC-157 | Five studies exist; the largest musculoskeletal one is a telephone survey | Published record |
| Human trials of full-length thymosin beta-4 | Yes — eye drops for dry eye and for corneal damage, topical gel for pressure sores | These are surface applications of a different molecule |
| Human dose that has ever been established for either | None | No dose-finding study exists for either compound in a person |

[[embed:source:s3]]

## Two registry entries were filed in February 2026, and one of them says it is a made-up example

That last table has a date on it. As of 4 August 2026 ClinicalTrials.gov holds two entries naming these compounds. Both were filed by the same sponsor, Hudson Biotech, both give a start date in the first week of February 2026, and both are marked recruiting. Read that for what it is. A registry entry is a filing by the sponsor. Nobody at the registry checks it, and neither entry has posted a result.

| Trial | Compound | People | Design | What it measures | When |
|---|---|---|---|---|---|
| NCT07437547 | BPC-157 | 120 planned | Phase 2, randomised, double-blind, placebo-controlled. Grade II hamstring strain confirmed on MRI. Injection under the skin, once daily for 14 days, given by study staff | Days until return to unrestricted sport, at 8 weeks; and change in injury volume on MRI at day 14, read by radiologists who do not know the group | Started 2 February 2026 |
| NCT07487363 | TB-500 | 80 planned | Phase 1/2, randomised, double-blind, placebo-controlled, stepped dose escalation. Adults with stable atherosclerotic heart disease | Side events at 12 weeks, serious events at 28 days, plus how the body absorbs and clears it | Started 5 February 2026 |

[[embed:source:s2]]

Now read the second row against its own record. The public summary of NCT07487363 opens: "This fictional study is an example of a ClinicalTrials.gov-style record." Its dose field says the levels "are not provided in this public example." That entry is a template, not a trial, and any page citing it as proof that TB-500 is being tested in people is citing a placeholder. The same sponsor filed eight entries of this shape between 2 and 15 February 2026 — covering BPC-157, TB-500, GHK-Cu, MOTS-c, melanotan II, tesamorelin, tirzepatide and retatrutide, one study site each — and that is the company the first row keeps.

The first row is the one that would matter. NCT07437547 has an imaging endpoint read by people who do not know who got what, which would make it the first study capable of saying whether BPC-157 changes the size of a real injury in a real person. Its listed site is Peking University Shenzhen Hospital.

Neither entry tests the pair. Neither enrols anyone with a back problem. And a filing is not a finding: until NCT07437547 posts results, the number of randomised human results for either compound in a torn tissue stays at zero.

## Forty people wrote down what happened to them, and here is the tally

Self-reports are not evidence of whether a compound works. They are evidence of what happens to people who take it, which is a different and still useful thing — it is where side effects, dose ranges and failure rates show up first, years before anybody runs a trial.

Forty reports were counted. The rule for counting: the person had to state an outcome for themselves. Commentary about the compounds, dosing instructions with no result attached, and posts written mid-run before any outcome were excluded — sixteen entries were dropped on that rule.

| Outcome | Count | Share |
|---|---|---|
| Said it helped | 21 | 52.5% |
| Said nothing changed | 15 | 37.5% |
| Said something got worse | 4 | 10% |
| **Total counted** | **40** | |

Every one of these is anecdotal. None was blinded, none had a control, and people who get a result post more readily than people who do not, so the true no-effect share is almost certainly higher than 37.5%.

### The twenty-one who said it helped

[[embed:source:s4]]

[[embed:source:s5]]

[[embed:source:s6]]

[[embed:source:s7]]

[[embed:source:s8]]

[[embed:source:s9]]

[[embed:source:s10]]

[[embed:source:s11]]

[[embed:source:s12]]

[[embed:source:s13]]

[[embed:source:s14]]

That last one is worth its own line. Pain that vanishes in days and returns within days of stopping is the signature of something calming irritation, not of something rebuilding a tendon. Rebuilt tissue does not un-rebuild in a week. Several of the fast-relief reports fit that shape better than they fit a repair story.

The remaining ten in this group: u/DifficultReach2720 (foot, "basically fully healed" at three months), u/NoInvestigator7249 (elbow, range of motion back to 100%), u/frequentflyernine11 (wrist, close to previous strength after seven vials, still minor pain), u/sdBiotch ("not a miracle by any means but I can improve mobility"), u/SanketJ1986 (pain down in the treated arm, no change in the other), u/Quacka-moo ("It has helped a bit but I expected more"), @drmarlonperalta (ten years of low back pain from a herniated disc, "a 6-week cycle removed this distraction permanently"), @AJA_Cortes (L5-S1 flare, oral BPC-157 at 2,000 mcg a day, pain free in seven days, and his own comment was "maybe, maybe not — I'm always open to possibility of placebo"), @Breedlove22 (ran both, credited the pair), and @mindpumpsal.
[[embed:source:s15]]

[[embed:source:s16]]

### The fifteen who said nothing changed

[[embed:source:s17]]

[[embed:source:s18]]

[[embed:source:s19]]

[[embed:source:s20]]

[[embed:source:s21]]

[[embed:source:s22]]

[[embed:source:s23]]

[[embed:source:s24]]

[[embed:source:s25]]

The other six: u/Dizzy-Breakfast-9405 (a month, thoracic pain, no results), u/kayfab (capsules, ligament, nothing), u/Acrobatic-Car3352 (nine days into a blend, Achilles, no changes), u/forsaken3400 (day 5, shoulder, nothing beyond possibly better sleep), u/mite189 (the tear did not heal faster; recovery came with prescribed isometric work), u/mudra311 (elbow, "I felt better before the BPC as well").

### The four who got a new problem

[[embed:source:s26]]

[[embed:source:s27]]

[[embed:source:s28]]

[[embed:source:s29]]

Two of those four describe swelling or fluid at or near the treated site, and both compounds are proposed to grow blood vessels, which is a mechanism that would produce exactly that. The blurred vision report has no mechanism attached to it and no follow-up.

### What the tally can and cannot decide

It cannot decide whether the compounds work. Half a sample reporting improvement in a condition where most soft-tissue injuries improve on their own over the same weeks is what a completely inert substance would also produce.

It can decide four things. First, roughly one person in ten reports a new problem, and that number belongs in any decision. Second, the doses in real use cluster at 250 to 500 mcg a day for BPC-157, which is well below the milligram doses in every human study of BPC-157 that has been published. Third, the fast-relief-then-relapse pattern is common enough to suggest that much of what people feel is irritation settling rather than tissue rebuilding. Fourth, the failures are specific and repeated — several people ran it three separate times with nothing to show.

## Twelve of the forty ran both compounds, not one

The tally above mixes people who took BPC-157 alone with people who ran the pair. Splitting out only those who explicitly ran both:

| Outcome | Count |
|---|---|
| Helped | 6 |
| Nothing changed | 4 |
| Something got worse | 2 |
| **Total** | **12** |

Six helped out of twelve, against twenty-one out of forty in the whole set. Twelve people is far too small to compare against anything, and a 50% versus 52.5% gap means nothing at that size. What the split does show is that no signal jumps out in favour of running both, which is the same direction the rat study pointed.

## Turning a vial of powder into marks on a syringe

Both compounds ship as a dry white powder in a sealed glass vial, usually 5, 10 or 20 mg. You add bacteriostatic water — sterile water with 0.9% benzyl alcohol in it as a preservative, which is what makes it safe to put a needle into the same vial repeatedly. Plain sterile water works chemically but has no preservative, so it is a one-entry proposition.

The dosing tool is a U-100 insulin syringe. U-100 means 100 marks per millilitre, so one mark is 0.01 mL. Two lines of arithmetic give you everything:

- Concentration in mcg per mL = total mcg in the vial ÷ mL of water added.
- Mcg per mark = concentration ÷ 100.

Worked all the way through, for a 10 mg vial with 2 mL of water:

1. 10 mg = 10,000 mcg.
2. 10,000 mcg ÷ 2 mL = 5,000 mcg per mL.
3. 5,000 ÷ 100 = 50 mcg per mark.
4. A 500 mcg dose = 500 ÷ 50 = 10 marks = 0.10 mL.

| Vial | Water added | Concentration | Mcg per mark | 250 mcg | 500 mcg | 1 mg | 2.5 mg | Doses per vial at 500 mcg |
|---|---|---|---|---|---|---|---|---|
| 5 mg | 1.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 50 marks | 10 |
| 5 mg | 2.0 mL | 2,500 mcg/mL | 25 | 10 marks | 20 marks | 40 marks | 100 marks | 10 |
| 10 mg | 2.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 50 marks | 20 |
| 10 mg | 3.0 mL | 3,333 mcg/mL | 33.3 | 7.5 marks | 15 marks | 30 marks | 75 marks | 20 |
| 20 mg | 4.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 50 marks | 40 |

Adding more water does not change how much compound is in the vial. It changes only how many marks carry a dose. Below about five marks the graduations on a U-100 barrel are too close together to read reliably, which is the practical argument for the more dilute fills when the dose is small.

Handling that ruins the peptide is easy to do by accident. Bring the vial to room temperature first. Run the water slowly down the inside wall rather than squirting it onto the powder. Swirl until clear, never shake — shaking a peptide solution tears the molecules apart at the air-water boundary and makes them clump, and clumping is the exact mechanism FDA named when it raised the risk that the immune system reacts to these products.

Once water is in, a vial keeps about four weeks in a fridge at 2–8 °C. That is the preservative's specification, not a stability measurement on these peptides — nobody has run one. Do not freeze a reconstituted vial; freezing and thawing makes short peptides clump.

## A full day of both compounds, in marks and millilitres

Two common daily patterns, both at 5,000 mcg/mL:

| Pattern | BPC-157 | TB-500 | Total volume | Injections per day |
|---|---|---|---|---|
| Both daily, low | 500 mcg = 10 marks = 0.10 mL | 500 mcg = 10 marks = 0.10 mL | 0.20 mL | 2 |
| BPC daily, TB twice weekly | 500 mcg = 10 marks = 0.10 mL | 2.5 mg = 50 marks = 0.50 mL, Monday and Thursday | 0.10 mL most days, 0.60 mL twice a week | 1, or 2 twice a week |

Do not mix the two in one syringe. They have different concentrations, different volumes and different schedules, and combining them makes every future dose adjustment guesswork.

Where the needle goes was never resolved by the animal work, because the animals were dosed into the belly cavity or by drinking water, almost never at a site chosen to be near an injury. Several of the strongest structural results in rats — cut ligament, muscle torn off bone, spinal cord — came from animals drinking the compound in water and still repairing a specific distant injury. There is no head-to-head study showing an injection near the injury beats an injection into abdominal fat.

## Eight weeks of materials, priced with the arithmetic shown

Prices below are from one named research-chemical vendor, Nationwide Peptides, read on 4 August 2026. They publish a range across vial sizes rather than a per-size price, so the two endpoints are what can be quoted exactly.

- BPC-157: $42.00 for the smallest listed size (5 mg), $63.00 for the largest (20 mg).
- TB-500: $38.00 for the smallest listed size (5 mg), $61.00 for the largest (10 mg).

[[embed:source:s30]]

Eight weeks is 56 days. The arithmetic:

**BPC-157 at 500 mcg a day.** 56 days × 500 mcg = 28,000 mcg = 28 mg.
- Buying 5 mg vials: 6 vials (30 mg) × $42 = **$252**. Cost per day = $252 ÷ 56 = **$4.50**.
- Buying 20 mg vials: 2 vials (40 mg) × $63 = **$126**. Cost per day = $126 ÷ 56 = **$2.25**. Twelve milligrams get discarded, because a 20 mg vial at 500 mcg a day is 40 doses and a reconstituted vial only lasts about 28 days. Even throwing that away, the big vial is half the price of the small ones.

**TB-500 at 500 mcg a day.** 28 mg over the run. 3 × 10 mg vials × $61 = **$183**. Cost per day = **$3.27**. A 10 mg vial at 500 mcg a day is 20 doses, which fits inside the four-week window with nothing wasted.

**TB-500 at 2.5 mg twice a week.** 5 mg a week × 8 = 40 mg. 4 × 10 mg vials × $61 = **$244**. Cost per day = **$4.36**. Each vial is 4 doses, so exactly two weeks per vial.

**Consumables.** Bacteriostatic water, insulin syringes, alcohol swabs: about $30 for a run at retail.

| What is run | Eight-week materials | Per day |
|---|---|---|
| BPC-157 alone, 500 mcg/day, 20 mg vials | $126 + $30 = **$156** | $2.79 |
| TB-500 alone, 500 mcg/day | $183 + $30 = **$213** | $3.80 |
| Both, 500 mcg/day each, cheapest vial sizes | $126 + $183 + $30 = **$339** | $6.05 |
| Both, 500 mcg/day each, smallest vial sizes | $252 + $183 + $30 = **$465** | $8.30 |
| Both, BPC daily + TB 2.5 mg twice weekly | $126 + $244 + $30 = **$400** | $7.14 |

Adding the second compound to a BPC-157-only run costs $183 over eight weeks and doubles the injections. That is the price of the only thing the pairing buys, and the one experiment that measured whether it buys anything found that it did not.

None of these prices buys a verified product. There is no pharmacy channel for either compound, no monograph, and no requirement on any vendor to be accurate. A batch-specific purity test and mass-spectrometry identity report is the only thing standing between a buyer and a vial of something else, and at least one of the reports above — the man who ran 10 mg with no result and wondered whether his source was fake — is exactly that failure mode.

## Twelve weeks with a torn rotator cuff, hour by hour and dollar by dollar

One case, walked all the way through, with the numbers attached and the failure conditions written down before the start.

**Week 0 — what exists.** Partial-thickness rotator cuff tear confirmed on MRI. Pain 6/10 overhead, 2/10 at rest. Cannot sleep on that side. MRI already done: $400–$1,800 cash, $250–$400 typical Medicare allowable, 1 hour. Four things get written down as the baseline, because a result nobody measured is a result nobody has: pain overhead on a 0–10 scale, degrees of pain-free overhead reach measured against a doorframe, nights woken per week, and heaviest weight pressed overhead for five reps.

**Weeks 1–12 — the part that actually has evidence.** Progressive loading, twice a week with a therapist for the first six weeks then once. 18 visits at $75–$150 = $1,350–$2,700, about 18 clinic hours plus 20 hours of home work. This is the arm of the plan with randomised human trials behind it, and it is also the largest line in both the money column and the hours column. Anything else is added on top of it, never instead of it.

**Weeks 1–8 — the compounds, if they are run.** BPC-157 500 mcg a day and TB-500 500 mcg a day, into abdominal fat. Materials $339. Time: about 4 minutes a day for two injections, 56 days, so 3.7 hours over the run, plus roughly 20 minutes total spent reconstituting five vials.

**Week 4 — first decision point.** The stopping rule, set in advance: if nights woken per week has not fallen at all by week 4 and pain-free overhead reach has not gained at least 10 degrees, the compounds stop. That is not a strict test — a rotator cuff on a good loading programme improves over four weeks anyway — but a run showing zero movement on both measures at four weeks has failed its own premise. Money saved by stopping there: $170.

**Week 8 — second decision point.** Compounds end regardless. Both measures are read again. Anything that has improved from here belongs to the loading programme, which is running either way, and that is the point of ending the run while therapy continues — it separates the two.

**Week 12 — the state at the end.** Running total: $1,350–$2,700 in physical therapy, $339 in materials, $400–$1,800 for the MRI, so **$2,089 to $4,839**. Patient time: about 42 hours. The expected result on the loading programme alone, from the trial literature, is substantial improvement in pain and function in most partial-thickness tears at twelve weeks without surgery. The compounds cannot be credited for that, because a single person running one arm cannot separate a treatment from the natural course. What one person can learn is whether they got a side effect, whether they tolerated it, and what it cost.

**What would count as failure.** No change on either baseline measure at week 4. A new problem — swelling, worsening pain in an untreated joint, anything visual. Or pain that improves during the run and returns within two weeks of stopping, which points at irritation settling rather than tissue rebuilt.

## In United States law neither one is a medicine

Neither BPC-157 nor TB-500 is an approved medicine in the United States. Neither is banned outright either. Both sit in a specific and awkward place, and the FDA page that defines it is public.

Both appear on FDA's list of bulk drug substances "nominated but withdrawn" — substances that were put forward for use in compounded medicines, placed in the agency's category 2 for possible significant safety risks, and then pulled by whoever nominated them. FDA's stated concerns, in its own words, are that compounded products containing BPC-157 "may pose risk for immunogenicity for certain routes of administration" and that for the thymosin beta-4 fragment "FDA has not identified any human exposure data" and "lacks important information regarding any safety issues raised by this drug, including whether it would cause harm if administered to humans."

[[embed:source:s31]]

What follows from that, in plain terms:

- No pharmacy can lawfully compound either one. Neither is on the 503A list that traditional compounding pharmacies work from, nor the 503B list that outsourcing facilities work from.
- On 23–24 July 2026 FDA's Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, in favour of allowing BPC-157 and TB-500 to be compounded, against FDA's own written recommendation. That vote is advice. It does not bind FDA, it does not make either an approved drug, and the rulemaking it triggers realistically takes eight to twelve months.
- "Research use only" on a vial is a shipping label, not a legal category that makes anything safe or lawful to inject.

[[embed:source:s32]]

## Both are banned in tested sport, at all times

Anyone who competes under anti-doping rules — collegiate, professional, masters, national federation, Olympic pathway — is exposed, and so is anyone serving in the United States military.

- BPC-157 is named in the WADA 2026 Prohibited List under S0, non-approved substances, prohibited at all times, in and out of competition.
- TB-500 is named under S2.3, growth factors, as "Thymosin-ß4 and its derivatives e.g. TB-500", also prohibited at all times, in the harsher non-specified tier.
- The S2.3 catch-all covers substances affecting "muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity" — the exact reason someone would take either one is written into the prohibition.
- Strict liability applies. Intent does not matter, and who recommended it does not matter. The Canadian Centre for Ethics in Sport imposed a four-year ban on an athlete for exactly this pair.
- Sanctions can be imposed with no positive test at all, on an admission, a possession finding, or a purchase record.
- The Department of Defense lists BPC-157 on its prohibited supplement ingredients list and states plainly that it is not a dietary ingredient, it is an unapproved drug.

[[embed:source:s33]]

Off-season use is a violation. There is no window in which either compound is allowed.

## What is solid, what is a guess, and what nobody knows

**Solid.**
- TB-500 raised the breaking strength of a repaired rat Achilles tendon against control, 8 animals per arm, four weeks, p < 0.05.
- BPC-157 improved healing in rat tendon-to-bone, ligament, muscle, sciatic nerve and spinal cord models, across many separate experiments from largely one research group.
- Tested head to head in rats, the combination beat neither compound alone.
- Neither is an approved medicine, neither is lawfully compoundable, and both are banned in tested sport at all times.
- Doses in real use are 250 to 500 mcg a day, well below every published human dose of BPC-157, which were all milligram doses.

**A guess.**
- That any rat dose translates to a human dose. Scaling the standard rat dose of 10 µg/kg straight to a 70 kg adult gives about 0.7 mg a day, roughly twice what most people take.
- That injecting near the injury beats injecting into abdominal fat. Nothing has compared them.
- That the vial contains what the label says. Nothing requires it to.
- That the two compounds are worth running together. One experiment says no, and it has the limits set out above.

**Nobody knows.**
- What either compound does in a person over months. The longest human exposure on record for BPC-157 is two weeks in a Phase 1 study.
- Whether the immune system reacts to repeated injections of either. FDA named this as its specific concern and no one has measured it.
- What happens if either is taken by someone with an undiagnosed cancer. Both are proposed to grow blood vessels, which is also what a tumour needs, and thymosin beta-4 is overexpressed in many solid tumours.
- Whether the fragment sold as TB-500 does anything the full protein does, outside the one rat tendon study.

For the version of this stack aimed at a worn disc and nerve pain, with ARA-290 added for the nerve itself, the mechanism table, the evidence grades and the three-compound arithmetic are set out separately.

[[embed:wolverine-stack-ara-290]]

[[embed:what-are-peptides-herniated-disc]]

[[embed:degenerative-disc-disease]]

[[embed:ara-290]]


## Claims (48 of 52 ranked)

- **c12** [human w=?] The FDA's July 2026 review says it found no data at all on people who have taken products containing the thymosin beta-4 fragment.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
  - sources: s3
- **c4** [preclinical w=?] In a rat Achilles tendon repair, TB-500 at 60 micrograms per kilogram per day raised the maximum load the tendon took before failing, against control, at p < 0.05.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
  - sources: s1
- **c6** [preclinical w=?] In that same experiment BPC-157 at 10 micrograms per kilogram per day came out numerically better than control, but it did not reach statistical significance on the total scores.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
  - sources: s1
- **c7** [preclinical w=?] The only experiment ever to test BPC-157 and TB-500 together against each one alone found that putting them together added nothing over either one by itself.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
  - sources: s1
- **c402** [preclinical w=?] That experiment ran 32 rats, 8 to a group, with a daily injection into the belly for four weeks.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
  - sources: s1
- **c10** [mechanistic w=?] What is sold as TB-500 is not full-length thymosin beta-4, and the FDA wrote that distinction down in July 2026.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
  - sources: s3
- **c22** [mechanistic w=?] At Nationwide Peptides list prices read on 4 August 2026, eight weeks of both compounds at 500 micrograms a day each costs 339 US dollars in materials, consumables included.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
  - sources: s30
- **c23** [mechanistic w=?] Neither BPC-157 nor TB-500 is an approved medicine in the United States.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
  - sources: s31
- **c24** [mechanistic w=?] On 23 to 24 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, in favour of letting BPC-157 and TB-500 be compounded, against the FDA's own written recommendation.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
  - sources: s32
- **c25** [mechanistic w=?] BPC-157 is named in the WADA 2026 Prohibited List under S0, non-approved substances, banned at all times.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
  - sources: s33
- **c405** [mechanistic w=?] Results obtained with the 43-amino-acid protein do not carry over to the 7-amino-acid fragment people actually buy.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
  - sources: s3
- **c414** [mechanistic w=?] That works out to 6.05 dollars a day.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
  - sources: s30
- **c415** [mechanistic w=?] Adding TB-500 to a BPC-157-only run costs 183 dollars over the eight weeks and doubles the number of injections.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
  - sources: s30
- **c416** [mechanistic w=?] Both sit on the FDA's list of bulk drug substances that were nominated and then withdrawn, placed in category 2 for possible significant safety risks.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
  - sources: s31
- **c417** [mechanistic w=?] Neither one is on the 503A or the 503B compounding list.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
  - sources: s31
- **c418** [mechanistic w=?] That vote is advisory and does not bind the FDA, and the rulemaking it sets off realistically takes eight to twelve months.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
  - sources: s32
- **c419** [mechanistic w=?] TB-500 is named under S2.3 as a thymosin beta-4 derivative, also banned at all times, in the non-specified tier.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
  - sources: s33
- **c420** [mechanistic w=?] Strict liability applies, so a sanction can follow from an admission or a purchase record with no positive test at all.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
  - sources: s33
- **c27** [speculative w=?] Scaling the standard rat dose of 10 micrograms per kilogram straight across to a 70 kilogram adult gives about 0.7 milligrams a day, roughly twice what most people take.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
- **c422** [speculative w=?] That scaling is an assumption and not a measured human dose, and no dose-finding study exists for either compound in a person.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
- **c11** [human w=?] No controlled human trial of BPC-157 and TB-500 together exists for any condition at all. Searching the registries and the literature turns up nothing.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s3, s34
- **c13** [human w=?] NCT07437547 is a Phase 2 randomised, double-blind, placebo-controlled trial of BPC-157 in 120 planned people with a Grade II hamstring strain confirmed on a scan.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s2
- **c14** [human w=?] NCT07487363 is a Phase 1/2 randomised, double-blind, placebo-controlled trial of TB-500 that steps the dose up, in 80 planned adults with stable narrowed heart arteries.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_unknown
- **c406** [human w=?] Study staff give that injection under the skin once a day for 14 days, and the trial started on 2 February 2026.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s2
- **c407** [human w=?] What it measures is return to unrestricted sport at 8 weeks, and the size of the injury on a blinded scan at day 14.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s2
- **c408** [human w=?] That one started on 5 February 2026 and measures side events at 12 weeks, serious events at 28 days, and how the body absorbs and clears the compound.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_unknown
- **c5** [preclinical w=?] In that same experiment TB-500 improved the Bonar tissue score at p = 0.016 and the Movin score at p = 0.017.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s1
- **c8** [preclinical w=?] BPC-157 improved healing in rats across many separate experiments, covering tendon-to-bone, cut ligament, crushed muscle, cut sciatic nerve and spinal cord injury.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s34, s35
- **c9** [preclinical w=?] Full-length thymosin beta-4, 1 microgram of it set into the gap of a cut rat knee ligament in fibrin glue, produced even fibre bundles and significantly more mechanical strength than control.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s35
- **c403** [preclinical w=?] Under a collagen stain, the TB-500 group had the most orderly type I collagen fibres of any group in the study.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s1
- **c404** [preclinical w=?] Nearly all of those experiments came out of a single research group.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s34, s35
- **c1** [mechanistic w=?] BPC-157 is thought to work on the blood supply step of repair, growing new vessels into damaged tissue by switching on VEGF and the nitric oxide system that widens vessels.
  - who_claims: opus-5 (claude-code)
  - slot: what_it_is
  - sources: s34, s35
- **c2** [mechanistic w=?] TB-500 is a seven-amino-acid fragment of thymosin beta-4, covering residues 17 to 23 with the front end capped, and the stretch it copies is the part that grabs actin.
  - who_claims: opus-5 (claude-code)
  - slot: what_it_is
  - sources: s3, s35
- **c3** [mechanistic w=?] Tendon, ligament and the adult disc between two vertebrae all heal slowly because blood barely reaches them.
  - who_claims: opus-5 (claude-code)
  - slot: what_it_is
  - sources: s35
- **c20** [mechanistic w=?] A 10 mg vial mixed with 2 mL of bacteriostatic water gives 5,000 micrograms per mL, which works out to 50 micrograms per mark on a U-100 insulin syringe.
  - who_claims: opus-5 (claude-code)
  - slot: what_it_is
- **c21** [mechanistic w=?] A mixed vial keeps about four weeks at 2 to 8 degrees Celsius.
  - who_claims: opus-5 (claude-code)
  - slot: what_it_is
- **c28** [mechanistic w=?] Three separate 2026 reviews in orthopaedics and sports medicine went through this literature independently — one in Sports Medicine, one in the American Journal of Sports Medicine, and one in the Journal of the American Academy of Orthopaedic Surgeons.
  - who_claims: opus-5 (claude-code)
  - slot: what_it_is
  - sources: s34, s35
- **c400** [mechanistic w=?] Grabbing actin frees up the internal scaffolding a repair cell uses to crawl into a wound.
  - who_claims: opus-5 (claude-code)
  - slot: what_it_is
  - sources: s3, s35
- **c401** [mechanistic w=?] The centre of an adult disc has no vessels in it at all. It is fed by seepage across cartilage end plates that stiffen and calcify as a person gets older.
  - who_claims: opus-5 (claude-code)
  - slot: what_it_is
  - sources: s35
- **c412** [mechanistic w=?] So a 500 microgram dose is 10 marks on the syringe, or 0.10 mL.
  - who_claims: opus-5 (claude-code)
  - slot: what_it_is
- **c413** [mechanistic w=?] That four-week figure is the specification for the benzyl alcohol preservative, not a stability measurement on either peptide, because nobody has run one.
  - who_claims: opus-5 (claude-code)
  - slot: what_it_is
- **c423** [mechanistic w=?] All three landed in the same place. The animal record is real, the human record is absent, and the products on sale are unregulated.
  - who_claims: opus-5 (claude-code)
  - slot: what_it_is
  - sources: s34, s35
- **c15** [anecdotal w=?] Forty first-person reports were counted, under a stated rule that the person had to say what the outcome was for themselves. Sixteen more entries were dropped for failing that rule.
  - who_claims: opus-5 (claude-code)
  - slot: who_claims_what
  - sources: s4, s5, s6, s7, s8, s9, s10, s11, s12, s13, s14, s15, s16, s17, s18, s19, s20, s21, s22, s23, s24, s25, s26, s27, s28, s29
- **c16** [anecdotal w=?] Twelve of the forty reports ran both compounds rather than one. 6 of those helped, 4 said nothing changed and 2 got worse.
  - who_claims: opus-5 (claude-code)
  - slot: who_claims_what
  - sources: s4, s5, s6, s11, s18, s19, s20, s26
- **c17** [anecdotal w=?] Doses in real use cluster at 250 to 500 micrograms a day for BPC-157, which is well below the milligram doses used in every published human study of it.
  - who_claims: opus-5 (claude-code)
  - slot: who_claims_what
  - sources: s6, s7, s8, s12, s13, s24
- **c18** [anecdotal w=?] One pattern comes up again and again in the reports. Relief arrives within days, and the problem comes back within days of stopping.
  - who_claims: opus-5 (claude-code)
  - slot: who_claims_what
  - sources: s14, s25
- **c19** [anecdotal w=?] Two of the four bad reports describe swelling or held fluid at or near the treated spot, which is what you would expect from something that grows blood vessels.
  - who_claims: opus-5 (claude-code)
  - slot: who_claims_what
  - sources: s27, s29
- **c409** [anecdotal w=?] Of the forty, 21 said it helped (52.5%), 15 said nothing changed (37.5%) and 4 said something got worse (10%).
  - who_claims: opus-5 (claude-code)
  - slot: who_claims_what
  - sources: s4, s5, s6, s7, s8, s9, s10, s11, s12, s13, s14, s15, s16, s17, s18, s19, s20, s21, s22, s23, s24, s25, s26, s27, s28, s29

## Voxel graph (52 atoms · 178 edges)
- full graph: https://miscsubjects.com/api/articles/wolverine-stack/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (35)
- chain valid: yes · head: `fd839b318a35d21d`

### s1 · source
- title: Biçer O, Adanir O, Güleryüz Y, Balci EC. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg, 23 July 2026. PMID 42542926
- url: https://pubmed.ncbi.nlm.nih.gov/42542926/
- quote: 32 rats, Achilles transection and repair, four arms of eight, four weeks intraperitoneal: control, BPC-157 10 µg/kg/day, TB-500 60 µg/kg/day, or both. TB-500 alone raised maximum load to failure (p<0.05), Bonar score (p=0.016) and Movin score (p=0.017). The combination did not confer additional benefits compared to either agent alone.
- hash: `597e23d54566917e`

### s2 · source
- title: NCT07437547 — A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI. Hudson Biotech. Recruiting, started 2 February 2026
- url: https://clinicaltrials.gov/study/NCT07437547
- quote: 120 participants planned. Subcutaneous injection once daily for 14 days versus placebo. Primary outcomes: time to return to unrestricted sport participation at 8 weeks, and change from baseline to day 14 in MRI-assessed hamstring injury volume by blinded central radiology review.
- hash: `cb27b6ea1a4706da`

### s3 · source
- title: FDA Briefing Document, Pharmacy Compounding Advisory Committee — TB-500-related bulk drug substances, July 2026
- url: https://www.fda.gov/media/193349/download
- quote: FDA has not identified any human exposure data for drug products containing Thymosin Beta-4, Fragment. FDA lacks important information regarding any safety issues raised by this drug, including whether it would cause harm if administered to humans.
- hash: `9a1a3396091c6f3a`

### s4 · source
- title: Reddit r/steroids — u/RGJJBrwn2022, 16 March 2025 — anecdotal, positive, ran both compounds
- url: https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4uao6/
- quote: Did 12 weeks of BPC and TB-500. After 10 weeks I went back to the ortho and he said the tear was gone.
- hash: `87f8ff2fe7935d49`

### s5 · source
- title: Reddit r/Biohackers — u/hraww, 9 April 2026 — anecdotal, positive, ran both compounds
- url: https://www.reddit.com/r/Biohackers/comments/1sgf3q0/bpc157_and_tb500_weekly_update/
- quote: 500mcg of BCP EOD and 500mcg of TB EOD. This is day 5 not even a full week and I could fucking cry because my shoulder feels 75% better that fast.
- hash: `450bffb152901046`

### s6 · source
- title: Reddit r/steroids — u/Blahblahblurred, 16 March 2025 — anecdotal, positive, ran both compounds
- url: https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4iwuk/
- quote: After some unsuccessful months, I stacked up BPC/TB 250mcg ED for 4 weeks. Pain completely gone after 3rd week.
- hash: `fd839b318a35d21d`

### s7 · source
- title: Reddit r/Biohackers — u/beach_nuts, 8 June 2026 — anecdotal, positive
- url: https://www.reddit.com/r/Biohackers/comments/1u09ium/bpc_157_tb500_side_effect_for_65_yrs_old/oqhs3hp/
- quote: Started BPC-157 three weeks after that injury, injecting 500mcg daily (left knee day 1, right knee day 2, etc). The chronic pain dissipated 3 weeks in and the injured knee felt stronger by week 4.
- hash: `82d61e78c543b4ce`

### s8 · source
- title: Reddit r/PEDs — u/SprinklesWise9857, 11 October 2025 — anecdotal, positive, self-assessed
- url: https://www.reddit.com/r/PEDs/comments/1o3g7qp/is_oral_bpc157_less_effective_than_injecting_it/niwej2s/
- quote: I partially tore my rotator cuff in early September. Injected 1500 mg BPC 157 for 3 weeks and I'm nearly fully recovered. I say this in terms of feel, not medical imaging.
- hash: `504e5b4c84a17a06`

### s9 · source
- title: Reddit r/Sciatica — u/kunukxathletix, 7 March 2026 — anecdotal, positive, sciatic pain
- url: https://www.reddit.com/r/Sciatica/comments/1rnicr5/pinched_sciatic_nerve/
- quote: I tried ever and eventually decided to try injectable BPC 157 and within a few weeks pain started to ease, well this could be random so I continued use after about 6-7 weeks sciatic pain was almost all the way gone
- hash: `134747f722a7fd3a`

### s10 · source
- title: X — @WovenDissent, 2026 — anecdotal, positive, elbow tendons
- url: https://x.com/WovenDissent/status/2071612933382037588
- quote: From a year of constant pain to pain free in both elbows - totally healed my tendons in 6 weeks. Shit is a miracle
- hash: `9f42f3ff5a6ba55d`

### s11 · source
- title: X — @MuroCrypto, 31 July 2026 — anecdotal, positive, herniated lumbar disc, ran both compounds
- url: https://x.com/MuroCrypto/status/2083184469956059529
- quote: In June I ran BPC-157 and TB-500 for about 6 weeks. Separate, normal doses like everyone recommends, injected into belly fat. After 3-4 weeks it already felt better.
- hash: `051a97a12e695c1b`

### s12 · source
- title: Reddit r/steroids — u/SwaveyyyD, 16 July 2023 — anecdotal, positive
- url: https://www.reddit.com/r/steroids/comments/150bge2/compounds_healing_compounds_bpc157_tb500/js5hfcw/
- quote: I did 500mcg every 8 hours (3x a day) for 2 weeks. After the two weeks there was a substantial difference in pain levels.
- hash: `bd28124f3ed9d651`

### s13 · source
- title: Reddit r/steroids — u/UnusuallyTarded11, 16 March 2025 — anecdotal, positive, rotator cuff
- url: https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4eq0n/
- quote: Used bpc-157 for a few weeks at 450- 900 mcg / day to heal a severely strained rotator cuff and it seems to have worked wonders.
- hash: `06bf795659c66bed`

### s14 · source
- title: Reddit r/steroids — u/MysterMumbles, 17 March 2025 — anecdotal, positive then relapse on stopping
- url: https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi9owhr/
- quote: Almost immediately the knee pain went away, although I have heard this is due to the anti-inflammatory effects rather than any actual healing. After three weeks when I stopped I noticed the knee pain came back almost immediately
- hash: `458b51a03b0c1843`

### s15 · source
- title: X — @drmarlonperalta, 4 June 2026 — anecdotal, positive, ten years of low back pain from a herniated disc
- url: https://x.com/drmarlonperalta/status/2062565899714925044
- quote: BPC-157. I've suffered for 10+ years with lower back pain from a herniated disc. I would constantly reposition myself for relief while working. The nagging pain in the background limited how deeply I could focus. A 6-week cycle removed this distraction permanently.
- hash: `f8138bc8ea5615c1`

### s16 · source
- title: X — @AJA_Cortes, 26 May 2024 — anecdotal, positive, L5-S1 flare, writer flags placebo himself
- url: https://x.com/AJA_Cortes/status/1794522474702336108
- quote: Decided to try to taking oral BPC157 at 2000mcg daily. Also got two deep tissue massages, and a chiro adjustment. 7 days later, pain free. Did the BPC157 help? Maybe, maybe not. Im always open to possibility of placebo.
- hash: `bbaf58fdfc3e66cf`

### s17 · source
- title: Reddit r/steroids — u/MjolnirCurls, 28 February 2018 — anecdotal, no effect
- url: https://www.reddit.com/r/steroids/comments/7zy7yi/compound_experience_saturday_bpc157/duz790a/
- quote: I did a total of 10mg at a dosage of 500 mcg each day, and noticed no difference. I am left to wonder if the source was just bunk because everybody else seems to love the stuff.
- hash: `33884e064699776f`

### s18 · source
- title: Reddit r/backpain — u/ImNotSchema, 19 August 2025 — anecdotal, no effect, ran both compounds
- url: https://www.reddit.com/r/backpain/comments/1mu96us/hlab27_sacroiliitis_on_mri_vs_disc_obliteration/
- quote: I also experimented with TB500 and BPC-157 peptides, but saw no improvement. The one thing that actually helped was Prednisone.
- hash: `b34974f3e31d4bc6`

### s19 · source
- title: Reddit r/PEDs — u/Itchy_Brain6340, 9 October 2023 — anecdotal, no effect, ran both compounds
- url: https://www.reddit.com/r/PEDs/comments/173pdv4/compounds_to_help_articular_cartilage_fissure_in/
- quote: I've taken tb500 and bpc157 before and found it did nothing.
- hash: `67f9ec056fe50e61`

### s20 · source
- title: X — @prax1s_mm, 30 July 2026 — anecdotal, no effect, third separate attempt, ran both compounds
- url: https://x.com/prax1s_mm/status/2082901582627184835
- quote: Did 3mg of BCP & 5mg of TB500 daily for two weeks into my elbow. It didn't do jack shit. This is my 3rd time trying peptides for various joint/tendon stuff and my 3rd time not noticing any improvement at all.
- hash: `df8d6c0776176865`

### s21 · source
- title: X — @LtCrandog, 30 July 2026 — anecdotal, no effect over ten years of use
- url: https://x.com/LtCrandog/status/2082758463407473109
- quote: Been taking bpc157 off and on for over 10 years and really don't think it does much. Apart from not really healing anything I've had random tendinitis pop up even while being on bpc.
- hash: `ee7962bd75744cfa`

### s22 · source
- title: Reddit r/Peptidesource — u/TheAwkwardEmu, 25 July 2026 — anecdotal, no effect at six weeks
- url: https://www.reddit.com/r/Peptidesource/comments/1v6e4g2/need_help_deciding_between_kpv_low_dose/
- quote: I am going to finish up a vial of BPC 157 that I've been injecting for about 6 weeks with no improvement.
- hash: `5be1dba643bf4e41`

### s23 · source
- title: Reddit r/moreplatesmoredates — u/Cr1ms0nSlayer, 8 May 2025 — anecdotal, no effect across two vendors
- url: https://www.reddit.com/r/moreplatesmoredates/comments/1kfp3uf/does_bpc157_increase_recovery_between_workouts/mr860tt/
- quote: I ordered from 2 different websites and I doubt the shit was fake but it didnt do anything for me besides cost me a few hundred
- hash: `0112d151703ca821`

### s24 · source
- title: Reddit r/steroids — u/jlthreequarters, 17 March 2025 — anecdotal, no effect, injected near the knee
- url: https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi6t9l6/
- quote: Been injecting 500mcg per day subq close to knee. Unfortunately have not seen any improvement in the knee/s.
- hash: `d58c35d471e3897d`

### s25 · source
- title: Reddit r/Biohackers — u/Trofas27, 16 June 2026 — anecdotal, effect then loss of effect
- url: https://www.reddit.com/r/Biohackers/comments/1u7ddu1/i_know_some_will_disagreebut_new_batch_of_bpc_157/
- quote: 6/12-seems to have stopped working. Upped to 6.5-7 units. No change. Will continue.
- hash: `ba50f6f8824e0c41`

### s26 · source
- title: Reddit r/backpain — u/Miserable_Fan1984, 16 September 2024 — anecdotal, got worse, herniated disc, ran both compounds
- url: https://www.reddit.com/r/backpain/comments/1fi50ar/bpc_157_and_tb_500_for_herniated_disc/
- quote: I started taking bpc 157 and tb 500 and 500mcg a day to help with healing but I have started to feel worse and have pain going down my leg again.
- hash: `e89045f40762b059`

### s27 · source
- title: Reddit r/PEDs — u/Illustrious_Buy_6545, 18 January 2026 — anecdotal, got worse in an untreated joint
- url: https://www.reddit.com/r/PEDs/comments/1qftcul/bpc157_gone_wrong/
- quote: While the shoulder is seemingly better (just a bit sore the first day), my knees got way worse and got inflamed pretty bad. Going to stop to see it gets better
- hash: `1a35a2c61e32bf07`

### s28 · source
- title: Reddit r/Biohackers — u/cityhunterspeee, 20 February 2026 — anecdotal, got worse, vision, ran a blend of both
- url: https://www.reddit.com/r/Biohackers/comments/1ra2m3p/1_month_of_bpc157_tb500_blend_reviewblurry_vision/
- quote: After weeks of bpc tb blend. I noticed my vision was getting worse and worse.. blurry..some days worse than others. Even just trying to focus at distance.
- hash: `98aeb95bf767f8d6`

### s29 · source
- title: Reddit r/climbharder — u/WeenieLoft, 22 February 2024 — anecdotal, got worse, swelling at the treated finger
- url: https://www.reddit.com/r/climbharder/comments/1axf2aa/my_experience_case_study_recovering_from_an_a2/
- quote: My finger started to stay very swollen all day and felt like it was retaining fluid. It became somewhat difficult to do finger rolls because it felt like my digits were too swollen in the skin to close properly.
- hash: `749c30295c41592b`

### s30 · source
- title: Nationwide Peptides — BPC-157 and TB-500 research-chemical listings, prices read 4 August 2026
- url: https://www.nationwidepeptides.com/products/bpc-157-peptide/
- quote: BPC-157 Peptide price range: $42.00 through $63.00, sizes 5 mg, 10 mg, 20 mg. TB-500 Peptide (TB4) price range: $38.00 through $61.00, sizes 5 mg, 10 mg. For Research Use Only. Not for human use.
- hash: `c0663513ccbc8108`

### s31 · source
- title: FDA — Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks, current as of 22 April 2026
- url: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- quote: Bulk drug substances nominated but withdrawn. This list of bulk drug substances previously in category 2 of the interim policies were withdrawn by the nominators. BPC-157: Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization.
- hash: `0657871c837b320d`

### s32 · source
- title: STAT News, 23 July 2026 — FDA advisory panel narrowly votes to allow compounding of unapproved peptides
- url: https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/
- quote: The Pharmacy Compounding Advisory Committee voted 8-6 with one abstention in favour of allowing BPC-157, KPV and TB-500 to be compounded, against FDA's own written recommendation.
- hash: `3fa2530076828a5e`

### s33 · source
- title: World Anti-Doping Code International Standard — Prohibited List 2026, effective 1 January 2026
- url: https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
- quote: S2.3 Growth Factors and Growth Factor Modulators: Thymosin-ß4 and its derivatives e.g. TB-500. S0 Non-Approved Substances: any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use. Prohibited at all times.
- hash: `3afeca26186385bc`

### s34 · source
- title: Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med, 12 April 2026. PMID 41966639
- url: https://pubmed.ncbi.nlm.nih.gov/41966639/
- quote: Independent 2026 review of the peptide musculoskeletal literature, covering BPC-157 and thymosin beta-4 products.
- hash: `2ec2e702bc4736cc`

### s35 · source
- title: Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med, January 2026. PMID 41476424
- url: https://pubmed.ncbi.nlm.nih.gov/41476424/
- quote: Independent 2026 primer on injectable peptide products used for musculoskeletal injury, written for orthopaedic and sports medicine physicians.
- hash: `ea1a5ad4aa922f72`

## Provenance (8 model passes)
- chain valid: yes · head: `7c94287583feac6c`

- write · claude-opus-5 · 2026-08-04T19:17 · hash `99cc7ef5f470`
- atomize-claims · opus-5 (claude-code) · 2026-08-04T19:28 · hash `a8d530cd855c`
- bind-proven-work-manifest · opus-5 (claude-code) · 2026-08-04T19:48 · hash `341d00df0dfc`
- backfill-claim-provenance · opus-5 (claude-code) · 2026-08-04T19:50 · hash `bbd590308df1`
- rebind-proven-work-manifest · opus-5 (claude-code) · 2026-08-04T19:53 · hash `027da378e513`
- assign-constitution-slots · opus-5 (claude-code) · 2026-08-04T19:56 · hash `bca270260cd6`
- assign-constitution-slots · opus-5 (claude-code) · 2026-08-04T19:57 · hash `45d27dbaff3f`
- rebind-proven-work-manifest · opus-5 (claude-code) · 2026-08-04T19:58 · hash `7c94287583fe`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/wolverine-stack/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/wolverine-stack/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"wolverine-stack","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest wolverine-stack|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim wolverine-stack|tier|assertion`
- **iMessage ask:** `wolverine-stack|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `wolverine-stack`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/wolverine-stack/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/wolverine-stack/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*